Malaria — Plasmodium Species and Management

• Liver Stage (Exoerythrocytic Schizogony): After inoculation by mosquito bite, sporozoites travel to the liver within minutes, enter hepatocytes via circumsporozoite protein-mediated invasion, and undergo asexual replication over 7-30 days (depending on species) without clinical symptoms. During this pre-erythrocytic phase, parasites are sequestered intracellularly and shielded from immune detection. P. vivax and P. ovale form hypnozoites—dormant forms persisting in hepatocytes for months to years—explaining relapse potential. Hepatocyte-derived cytokines (TNF-α, IL-6) prime systemic inflammation. Eventually, tens of thousands of merozoites rupture hepatocytes and invade erythrocytes, initiating the clinical symptomatic phase.

• Blood Stage (Erythrocytic Schizogony) and Hemolysis: Merozoites invade red blood cells using erythrocyte binding antigens and duffy antigen receptor for cytokines (DARC); P. vivax and P. ovale preferentially infect young RBCs (reticulocytes), while P. falciparum infects RBCs of all ages. Within infected RBCs, parasites digest hemoglobin, creating toxic hemozoin crystals and inducing oxidative stress. Asexual replication produces 8-32 daughter merozoites per infected RBC over 48-72 hours (48 hours for P. falciparum, P. vivax, P. ovale; 72 hours for P. malariae). Synchronized RBC rupture releases merozoites and hemozoin-containing host cell debris, triggering fever through pyrogenic cytokine release (TNF-α, IL-1β, IL-6) and explaining the classic paroxysmal fever pattern. Massive hemolysis produces anemia, elevated indirect bilirubin, elevated LDH, and decreased haptoglobin. P. falciparum expresses variant surface antigens (PfEMP1) on infected RBC membranes, mediating rosetting (binding uninfected RBCs and platelets) and cytoadherence to endothelial cells, causing vascular obstruction and sequestration in microvasculature—the pathophysiologic basis for severe malaria.

• **Cytoadherence and Sequestration in P. falciparum:** P. falciparum uniquely causes infected RBC cytoadherence to vascular endothelium via PfEMP1-receptor interactions (CD36, ICAM-1, thrombospondin), particularly in brain, lungs, kidneys, and placenta. This sequestration in deep microvasculature explains the severe complications unique to P. falciparum: cerebral malaria (mechanical obstruction plus local inflammation), acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and placental dysfunction in pregnancy. Parasite sequestration also allows parasites to evade splenic clearance by avoiding the peripheral blood during the mature schizont stage, contributing to high parasitemia levels.

• Immune Activation and Cytokine Storm: Pathogen-associated molecular patterns (PAMPs) from parasites—including GPI anchors, hemozoin, and parasite DNA—activate TLRs and inflammasomes in innate immune cells, releasing massive quantities of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ). While these cytokines control parasite replication, excess activation produces the systemic inflammatory response driving fever, headache, myalgias, and potentially shock. Nitric oxide depletion from immune activation impairs vascular endothelial function, promoting metabolic acidosis and organ dysfunction. In endemic areas, repeated infections generate partial acquired immunity through antibodies against variant parasite antigens, explaining why severe malaria predominantly affects non-immune individuals and children in endemic zones with subsequent protection.

• Metabolic Acidosis and Lactate Production: Parasites consume host cell glucose and produce lactate, while sequestration impairs microvascular perfusion and causes tissue hypoxia and anaerobic metabolism. This dual mechanism—increased parasite lactate production plus hypoxic lactate generation—produces severe metabolic acidosis, a hallmark of severe malaria with profound clinical consequences including altered mental status, cardiovascular collapse, and acute kidney injury.

• Thrombocytopenia and Coagulopathy: Parasites activate platelets through TLR and direct invasion, causing thrombocytopenia in >50% of malaria cases. Rosetting and sequestration activate coagulation cascades, potentially triggering disseminated intravascular coagulation (DIC), especially in severe P. falciparum malaria.

• Plasmodium falciparum: Most virulent species responsible for ~90% of malaria deaths worldwide. Dominant in Sub-Saharan Africa, Southeast Asia, and parts of South America. Causes the highest parasitemia levels, most rapid disease progression, and greatest risk for severe complications including cerebral malaria, acute kidney injury, acute respiratory distress syndrome, and fatal outcome. Chloroquine and sulfadoxine-pyrimethamine resistant throughout Africa; artemisinin resistance emerging in Southeast Asia (Cambodia, Myanmar, Thailand, Vietnam).

• Plasmodium vivax: Second most common species, predominant in Central/South America and parts of Asia-Pacific. Forms hypnozoites causing relapse months to years after initial infection; initial attack typically less severe than P. falciparum but relapses still clinically significant. Preferentially infects reticulocytes, often causing lower parasitemia. Duffy antigen-negative populations (common in African descent) are naturally resistant. Chloroquine resistance documented in Indonesia, Papua New Guinea, and parts of South America.

• Plasmodium ovale: Similar relapse potential to P. vivax via hypnozoites; geographically restricted to West Africa and scattered other regions. Infects young RBCs; generally milder clinical course but still causes significant morbidity.

• Plasmodium malariae: Quartan malaria with 72-hour fever cycles; rarely causes severe disease but chronic infection can develop. Found primarily in Africa, parts of Asia, and Pacific islands.

• Plasmodium knowlesi: Zoonotic malaria from macaques; emerging cause of severe malaria in Malaysia and other Southeast Asian countries. Similar severity to P. falciparum with risk of severe complications and AKI. Can progress rapidly to severe disease.

• Epidemiological Risk Factors: Travel to endemic areas (especially Sub-Saharan Africa), lack of chemoprophylaxis, antimalarial drug resistance in region of travel, pregnancy (increases placental sequestration risk), asplenia/functional hyposplenism, G6PD deficiency (important for antimalarial drug selection), immunosuppression (HIV/AIDS, medications), young age (<5 years in endemic areas), extremes of age.

• Fever (Paroxysmal Pattern): Classic tertian fever occurs every 48 hours in P. falciparum, P. vivax, P. ovale (merozoite release synchronized), while P. malariae produces quartan fever every 72 hours. Fever pattern may be irregular early in infection before synchronization; temperatures often spike to 40-41°C (104-106°F). Fever results from TNF-α and IL-1β release during RBC rupture. High fever in non-immune individuals contrasts with lower fevers in partially immune individuals.

• Rigors and Chills: Intense chills, shaking, and rigors precede fever spike, reflecting rapid hypothalamic temperature set-point elevation from pyrogenic cytokines. Patients describe profound cold despite high fever, often requiring multiple blankets despite room temperature comfort for observers.

• Headache and Myalgias: Intense headache, often frontal, accompanies fever and reflects CNS inflammation and cytokine effects. Severe myalgias, arthralgias, and back pain are characteristic. In P. vivax, joint pain may mimic acute rheumatologic disease ("breakbone fever" historical terminology).

• Gastrointestinal Symptoms: Nausea, vomiting, abdominal pain, and diarrhea occur in >50% of cases. Vomiting with high fever increases risk for severe dehydration and electrolyte abnormalities.

• Hepatosplenomegaly: Liver and spleen enlargement occurs in majority of cases due to reticuloendothelial inflammation and parasite sequestration. Hepatic dysfunction may manifest as elevated transaminases and hyperbilirubinemia.

• Anemia: Progressive hemolysis causes fatigue, pallor, dyspnea on exertion; hemoglobin may drop rapidly, especially with high parasitemia and repeated RBC rupture cycles.

• Neurological Manifestations: In uncomplicated malaria, patients may have irritability or mild confusion associated with high fever. Cerebral malaria (defined by impaired consciousness and parasitemia >5%) represents medical emergency with altered mental status ranging from subtle confusion to deep coma, seizures, and focal neurological deficits; exclusive to P. falciparum.

• Respiratory Manifestations: Tachypnea and hyperventilation reflect metabolic acidosis and malaria-associated acute respiratory distress syndrome (ARDS), particularly in P. falciparum. Patients may have rales, respiratory distress, and hypoxia.

• Hypotension and Shock: Severe malaria causes cardiovascular collapse through TNF-α-mediated vascular endothelial dysfunction, reduced nitric oxide production, hypovolemia from vomiting/diarrhea, metabolic acidosis, and sequestration. Shock carries extremely high mortality.

• Jaundice: Visible jaundice reflects severe hemolysis with indirect hyperbilirubinemia and potential hepatic involvement; suggests severe malaria.

• Physical Exam Findings: Fever, tachycardia, tachypnea, hepatosplenomegaly, jaundice, pallor, altered mental status (in severe disease), signs of dehydration.

• Atypical Presentations: In partially immune or semi-immune individuals (endemic areas), infection may present as chronic fever with minimal acute symptoms. In pregnant women, P. falciparum sequestration in placental microvasculature causes placental parasitemia without high peripheral parasitemia, making diagnosis challenging; severe anemia and hypoglycemia are prominent. Asymptomatic parasitemia can occur in endemic areas.

• Thick Blood Smear: Gold standard diagnostic test using Giemsa or Wright stain. Thick smear (20-40 μL of blood on slide, lysed RBCs) concentrates parasites, allowing detection at parasitemia levels as low as 5-10 parasites/μL. Sensitivity 95-99% when properly prepared but highly operator-dependent. Allows parasite quantification and species identification based on morphology: P. falciparum forms delicate ring forms and banana-shaped gametocytes; P. vivax and P. ovale infect reticulocytes (causing RBC enlargement, stippling, Schüffner dots); P. malariae appears in small RBCs; P. knowlesi can have high parasitemia. Interpretation requires experience; parasites may be missed in early infection or low parasitemia cases.

• Thin Blood Smear: Thin smear (single RBC layer) allows better morphological differentiation for species identification but less sensitive than thick smear, requiring examination of 200-300 fields to exclude diagnosis. Most useful for species determination in suspected cases.

• Rapid Diagnostic Tests (RDTs): Immunochromatographic tests detecting Plasmodium histidine-rich protein-2 (HRP-2 for P. falciparum), parasite lactate dehydrogenase (pLDH), or aldolase. Sensitivity 95-99% and specificity 94-99% for P. falciparum detection in high parasitemia (>100 parasites/μL) but lower sensitivity at low parasitemia levels. Point-of-care advantage allows rapid diagnosis in remote settings. HRP-2 persistence after treatment (up to 4 weeks) can cause false-positive results in previously treated patients. RDTs less sensitive for non-falciparum species and cannot quantify parasitemia.

• PCR (Polymerase Chain Reaction): Most sensitive and specific diagnostic modality, detecting parasitemia levels <1 parasite/μL and allowing species differentiation. Gold standard for confirming diagnosis in cases with negative microscopy but high clinical suspicion; particularly useful for low parasitemia cases and species identification. Not practical for acute diagnosis in most settings due to cost and time requirements but increasingly available in reference laboratories.

• Complete Blood Count: Reveals anemia (Hgb often 7-10 g/dL in severe cases), thrombocytopenia (present in >50% of cases), leukopenia or leukocytosis, and elevated absolute eosinophilia. Reticulocytosis may be prominent reflecting acute hemolysis. Normal to elevated WBC count typical in malaria (distinguishing from viral febrile illnesses).

• Blood Chemistry and Metabolic Panel: Elevated creatinine (acute kidney injury), elevated LDH (>1000 IU/L reflecting hemolysis), elevated indirect bilirubin, elevated transaminases (usually mild to moderate elevation), low albumin, metabolic acidosis (pH <7.35 with elevated lactate indicating severity), hypoglycemia (<40 mg/dL concerning for cerebral malaria), electrolyte abnormalities (hyperkalemia in AKI).

• Lactate and Acid-Base Status: Venous or arterial blood gas showing metabolic acidosis with elevated lactate (>5 mmol/L indicates severe malaria) represents key indicator of tissue hypoxia and poor prognosis. Lactate clearance monitored during treatment to assess response.

• Parasite Quantification: Parasitemia level (percentage of infected RBCs or parasites/μL blood) correlates with severity. High parasitemia (>5%) suggests greater risk for severe malaria; however, P. malariae typically remains low parasitemia despite severe disease. Serial parasitemia monitoring (should decrease by 25% daily with effective treatment) confirms treatment efficacy.

• Additional Tests: Reticulocyte count (elevated reflecting hemolysis), coagulation studies (PT/INR, PTT) if DIC suspected, blood cultures to rule out concurrent bacteremia, G6PD testing (before antimalarial therapy if indicated), pregnancy test in women of childbearing age.

• Diagnostic Criteria for Severe Malaria (WHO 2014): Any parasitemia level with one or more of the following: cerebral malaria (impaired consciousness, seizures, coma), severe anemia (Hgb <5 g/dL or transfusion requirement), acute kidney injury (serum creatinine >3 mg/dL or urine output <400 mL/day), pulmonary edema or ARDS, hypoglycemia (<40 mg/dL), metabolic acidosis (pH <7.35 or HCO3 <15 mEq/L), hyperparasitemia (>30% in P. falciparum), hemoglobinuria, jaundice, profound weakness/prostration, or hemorrhagic manifestations.

• Differential Diagnosis: Typhoid fever, dengue fever, yellow fever, leptospirosis, rickettsial infection, viral hepatitis, acute hepatitis, sepsis/bacteremia, relapsing fever, trypanosomiasis. Key distinguishing features: malaria's paroxysmal fever pattern, specific blood smear findings, absence of rash (except in some coinfections

Immediate triage — is this severe malaria?

• Risk-stratify first: any WHO severity criterion (coma, seizures, acidosis, AKI, ARDS, hypoglycemia, hyperparasitemia, jaundice with organ dysfunction) mandates parenteral therapy and ICU-level care. CDC advises treating suspected P. falciparum as an emergency while smears are pending.
• Supportive measures: frequent glucose checks (hypoglycemia is both disease- and quinine-driven), cautious rather than aggressive fluid boluses, seizure control, and blood cultures — concurrent gram-negative bacteremia (algid malaria) is common.

Severe malaria (CDC Guidelines for Treatment of Malaria in the United States)

• Artemisinin derivative, IV artesunate: first-line, FDA-approved and stocked by CDC; kills all asexual stages including young rings and rapidly reduces parasite biomass. Give a full oral follow-on course (artemether-lumefantrine preferred) once parasitemia falls and the patient tolerates PO.
• Interim bridging: if artesunate is not immediately at hand, CDC advises starting an oral artemisinin combination while it is obtained.
• Routine exchange transfusion is no longer recommended by CDC, even with hyperparasitemia; corticosteroids for cerebral malaria are harmful and contraindicated.

Uncomplicated malaria

• Artemisinin combination therapy, artemether-lumefantrine: first-line for chloroquine-resistant or unknown-resistance P. falciparum (essentially all of sub-Saharan Africa and Southeast Asia).
• Alternatives: atovaquone-proguanil; quinine sulfate plus doxycycline, tetracycline, or clindamycin; mefloquine only when others fail.
• Chloroquine (or hydroxychloroquine): reserved for documented chloroquine-sensitive regions — Central America west of the Panama Canal, Haiti, Dominican Republic.

Radical cure of relapsing species

• 8-aminoquinolines, primaquine or single-dose tafenoquine: added to chloroquine/ACT for P. vivax and P. ovale to eradicate hepatic hypnozoites. Quantitative G6PD testing is mandatory first.

Contraindicated

• Primaquine/tafenoquine: G6PD deficiency and pregnancy (fetal G6PD status unknown) — use weekly chloroquine suppression until delivery.
• Doxycycline/tetracycline: pregnancy and children under 8.
• Mefloquine: seizure or psychiatric disorders.

Emergencies — all essentially P. falciparum (and P. knowlesi)

• Cerebral malaria: PfEMP1-mediated cytoadherence and rosetting obstruct cerebral microvasculature with local cytokine injury. Signalled by unarousable coma, seizures, or malarial retinopathy (retinal whitening, vessel discoloration) on funduscopy. Highest-mortality complication; corticosteroids worsen outcome.
• Severe metabolic acidosis and shock: parasite lactate production plus sequestration-induced tissue hypoxia. Signalled by deep sighing (Kussmaul) respirations, lactate elevation, and a widened anion gap — the single best predictor of death.
• Acute kidney injury: sequestration in renal microvasculature plus hemoglobin cast nephropathy. Signalled by rising creatinine and oliguria; may require dialysis.
• ARDS/pulmonary edema: capillary leak and sequestration; may appear after parasite clearance and be precipitated by over-aggressive fluids. Signalled by new hypoxemia with bilateral infiltrates.
• Blackwater fever: massive intravascular hemolysis producing cola-colored urine with hemoglobinuria and precipitous hemoglobin fall.
• Hypoglycemia: parasite glucose consumption plus quinine-induced hyperinsulinemia; presents as sudden deterioration or seizure — always check a fingerstick.
• Splenic rupture: classically with P. vivax; left upper quadrant pain with hemodynamic collapse.
• DIC and bleeding: platelet activation and endothelial injury; mucosal bleeding with prolonged PT and falling fibrinogen.

Chronic and pregnancy-related

• Placental malaria: sequestration in intervillous space causes maternal anemia, low birth weight, and stillbirth despite low peripheral parasitemia.
• Quartan malarial nephropathy: chronic P. malariae immune-complex glomerulonephritis presenting as steroid-unresponsive nephrotic syndrome.

Treatment complications

• Post-artesunate delayed hemolysis: pitted, once-parasitized RBCs are cleared 1–3 weeks later; check hemoglobin at follow-up visits.
• Cinchonism from quinine: tinnitus, hearing loss, nausea; quinine also prolongs QT.
• Primaquine-induced hemolysis in unrecognized G6PD deficiency, and mefloquine neuropsychiatric toxicity.

• Fever in a returning traveler is malaria until excluded: the single best next step is a thick and thin Giemsa blood smear, repeated every 12–24 hours up to three times before ruling out disease. Do not defer treatment for a confirmatory PCR.
• Banana-shaped (crescentic) gametocytes and multiply-infected RBCs with appliqué/accolé ring forms = P. falciparum; Schüffner dots with enlarged RBCs = *P. vivax*/*P. ovale*; band-form trophozoites = P. malariae.
• Severe malaria means IV artesunate, not quinidine, not exchange transfusion. Per CDC, artesunate is first-line and routine exchange transfusion is no longer recommended.
• Relapse versus recrudescence is the classic distractor: *P. vivax*/*P. ovale* relapse from hepatic hypnozoites and need primaquine or tafenoquine; *P. falciparum*/*P. malariae* have no hypnozoites and instead recrudesce from persistent blood-stage parasites.
• Check G6PD before any 8-aminoquinoline. The stem that gives a Mediterranean or Southeast Asian man primaquine and then reports back pain, dark urine, and bite cells with Heinz bodies is testing this.
• Host genetics protect: Duffy antigen-negative erythrocytes resist P. vivax invasion (West Africans); sickle cell trait, HbC, thalassemias, and G6PD deficiency attenuate P. falciparum — a textbook example of balanced polymorphism.
• Hypoglycemia in a malaria patient is either the parasite or quinine-induced hyperinsulinemia; obtain a fingerstick glucose before attributing altered mentation to cerebral malaria alone.
• **Chronic P. malariae → nephrotic syndrome**; P. knowlesi looks like P. malariae on smear but behaves like P. falciparum clinically, with rapid rise in parasitemia.
• Steroids are wrong in cerebral malaria, and ACE inhibitors, doxycycline, and primaquine are all wrong in pregnancy.